Republic of the Philippines
Department of Health
METRO MANILA CENTER FOR HEALTH DEVELOPMENT

SUPPLEMENTAL/ BID BULLETIN NO. 1

IB No. 2025-078

Procurement of Doxycycline 100 mg capsule

This Supplemental/Bid Bulletin No. 1 is being issued to revise provisions/specifications in the Bidding Documents for a forecited project:

Query during Pre-bidding Conference:		
Technical Specification	**Query**	**Response of the End User Unit**
Form and Strength: 100 mg	Form and Strength: 100 mg / capsule	Form and Strength: 100 mg / capsule GRANTED
Doxycycline	Doxycycline / Doxycycline Hyclate	Doxycycline / Doxycycline Hyclate

Bidders are advised to use the **attached forms and submit them together with all required documents for the submission of bids on the 20th day of May 2025, 9:00 AM, Amphitheater.**

This Supplemental/Bid Bulletin No. 1 shall be integral to the Bidding Documents. All other provisions indicated in the bidding documents not affected by this Supplemental/Bid Bulletin No. 1 shall remain in effect.

For guidance and information of all concerned.

Issued this 13th day of May 2025 in MMCHD

Approved by:

SGD.
JEREMIAS FRANCIS Y. CHAN, MD, MPH
Licensing Officer V / BAC Chairperson

Republic of the Philippines
Department of Health
Metro Manila Center for Health Development

TECHNICAL SPECIFICATIONS

Item No. 1	**Doxycycline 100 mg capsule**	Qty./Unit	800,000 capsules
Name of Manufacturer:		Country of Origin (if applicable)	
Brand:		Model: (if applicable)	
ABC: P 1,000,000.00			
PURCHASER'S SPECIFICATION		STATEMENT OF COMPLIANCE	

SPECIFICATIONS:

Doxycycline / Doxycycline Hyclate

Route of Administration: Oral

Form and Strength: 100 mg / capsule

Additional Requirements: Certificate of Product Analysis (CPA) issued by the PFDA

Delivery Period: Forty-Five (45) calendar days after receipt of the Notice to Proceed

Delivery Place: DOH MMCHD Pasig Warehouse

B. Upon delivery, the following shall be complied with:

1. Shelf life:

Must be fresh commercial stock, with a minimum shelf life of eighteen (18) months remaining from the delivery date.

2. Packaging Instructions:

1. Standard packaging of the manufacturers as approved by the Philippine Food Drug and Authority

2. Primary Packaging: end-users specification

3. Standard Manufacturer/Distributor Packaging

3. Labeling instructions:
Standard labeling instruction as approved by FDA pursuant to Administrative Order No. 2016-0008

In addition to the labeling requirements of the PFDA:

a. The following should be legibly imprinted or stickered with a non-removable or permanent sticker or label that is binding and will leave residue and rip if removed

"Philippine Government Property-Department of Health" NOT FOR SALE Date of Manufacturer: Date of Expiry: Batch/Lot No.	
C. **Additional Requirements to be attached to Technical Specifications form arranged, numbered and tabbed as enumerated below**: 1. Valid and current Certificate Product Registration (CPR) or Valid Extension issued by the Philippine Food and Drug Administration (PFDA); The CPR must be valid for the entire period of the award. If the CPR is about to expire, the supplier must have submitted a copy of an application of renewal to the FDA at least 3 months before the expiry date (a copy of the expiring CPR which is stamped with an "Extension of Validity" shall be submitted as proof); [AO 2019-0041] 2. Valid and current License to Operate (LTO) for drug suppliers, distributors and traders issued by Philippine Food and Drugs Administration (PFDA). Provided, that the application for renewal was made timely as per DOH AO No. 2016-003: In case of expired LTO, the following copies may be submitted: (i) expired LTO; (ii) application for renewal with FDA document tracking number; and, (iii) Official Receipt as proof of payment of renewal of LTO 3. Product Insert/Product Information or downloaded from the internet and other manufacturer's unamended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data etc., as appropriate for cross-referencing statement of compliance to the technical specification in accordance to what is indicated in Technical Specifications; 4. Certification from the Manufacturer/Distributor/Importer/Wholesaler (as reflected in the Certificate of Product Registration of the product/s to be bid) that the Bidder is an authorized dealer or distributor of the product 5. Certificate of Compliance to the Electronic Drug Price Monitoring System (EDPMS) issued by either the Pharmaceutical Division (PD) of the DOH or DOH Regional Health Office/Centers for Health Development pursuant to DOH Administrative Order No. 2018-0020 and RA 9502 and its IRR; *In case of an expired Certificate of Compliance to the*	

EDPMS, refer to DOH Department Circular (DC) No.2023-0001, "Interim Guidelines on the Certificate of Compliance to Electronic Drug Price Monitoring System for Government Procurement Activities for Drugs and Medicines."	

D. Additional requirement by the Lowest/Single Calculated Bid (L/SCB) as part of post qualification:

You are requested to submit within (5) five days upon receipt of this notice three (3) copies of all documents needed for Post Qualification of the following documents:

1. Eligibility Documents
   i. (Mayor's Permit (latest annual and quarterly)
   ii. SEC/DTI Registration,
   iii. Tax Clearance)
2. Certificate of Registration from BIR
3. Income Tax Returns – latest payment
4. Bid Bulletin
5. Product Sample /Brochure
6. Authority from the Manufacturer to Distribute the Product
7. License to Operate
8. And other documents stated in BDS

1. One (1) original sample of the manufacturer's product to be submitted and returned after evaluation. The sample submitted and approved during the evaluation shall be the same item to be delivered upon contract award. The prototype of the labeling instruction must be part of the sample submitted; however, the technical specifications of the labeling instruction of the product must be complied with upon delivery.

E. Product Recall & Disposal:

1. The Supplier must ensure the quality of products and if there will be problems in the quality, the Supplier will recall and replace the products distributed in the regions/hospitals/treatment hubs/RHU/HC/BHSS based on Guidelines on Product Recall, FDA Circular No. 2016-012;

2. In instances of product recalls due to failures of suppliers and manufacturers to comply with standards of safety and quality, the cost associated with proper disposal/ destruction, handling or pull out from health facilities where these products have already been distributed shall be borne by the supplier (subject to the latest policy for disposal) (DOH Administrative Order (AO) No. 2019-0041)